Novotech Selected as Scrip Awards Finalist for Best Full-Service CRO
Novotech, the leading Asia Pacific biotech specialist CRO, joins
a prestigious group of global CROs as a finalist in the Scrip Award
for Best Full-Service CRO. This year the Award has been split into
two categories to separate the full-service providers from the
According to the Scrip Award organizers: "The Award for the Best
CRO acknowledges the critical role that CROs play in drug
development. Outsourcing is vital as the pharmaceutical industry
seeks to benefit more and more from these specialist companies'
experience in handling all aspects of clinical trials and other
research. Today, the role of the CRO has gone beyond the
traditional model of service-level agreements, to offer bespoke
clinical trial and other strategies; and CROs are increasingly
engaged in risk-sharing partnerships, or acting as a single-source
developer, while also remaining committed to core strengths."
The award judges are senior executives from biopharma and
investment firms, and clinical research leaders.
Novotech CEO Dr. John Moller said he was extremely pleased that
Novotech has been selected as a finalist and thanked the global
Novotech team for their hard work and commitment to a truly
customer focused approach to accelerate clinical development.
"This level of recognition is a credit to the team and shows our
Asia Pacific centered, global operations are setting new standards
for biotech CRO partnerships. Our deep experience, exceptional site
and investigator relationships - which also translates to patient
access - our project management approach focused on
problem-solving, ownership and flexibility, and our investments in
data and technology combine to deliver the full service, customer
focused solutions that biotechs need."
Novotech has operations across Asia Pacific and the US offering a
unique and unparalleled suite of CRO services for early to late
phase biotech clinical research.
Novotech has recently been benchmarked as a top 10 CRO among the
world's leading CROs and has also been selected for the Gene &
Cell Therapy Excellence Award. The company also has more than 50
Leading Site Partnership agreements and hundreds of long-term site
relationships across the Asia Pacific region.
Novotech is the leading Asia-Pacific biotech specialist CRO.
Novotech has integrated labs and phase I facilities and provides
drug development consulting and clinical development services
across all phases. It has been instrumental in the success of
approximately 4,000 clinical trials across a broad range of
therapeutic areas. Novotech is well-positioned to serve biopharma
clients conducting clinical trials in Asia-Pacific and the US. For
more information visit https://novotech-cro.com/contact
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427
Copyright 2022 JCN Newswire . All rights reserved.